As of May 2012 websites are required by law to gain your consent before applying cookies. We use cookies to improve your browsing experience. Parts of the website may not work as expected without them. By closing this message, you are consenting to our use of cookies. Close Learn more


Chronic Obstructive Pulmonary Disease


> Download your free sample > Contact us to find out more



This comprehensive coverage provides up-to-date opinions and forecasts based on extensive secondary research backed by a survey of 125 high prescribing pulmonologists and detailed discussions with KOLs.  Learn how the disease is currently treated, the unmet needs and how new market entrants (branded and generics/biosimilars) will affect the market in the future.

The Datamonitor Healthcare difference

What this package includes

Total number of physicians interviewed

US Japan France Germany Italy Spain UK
Pulmonologists 30 20 15 15 15 15 15


Coverage summary

Reports included in package
  • Epidemiology
  • Marketed drugs profiles
  • Pipeline drugs profiles
  • Patient-based drug forecasts
Countries evaluated US, Japan, France, Germany, Italy, Spain, UK
Patient-based drug forecast period 2012–21
Patient subpopulations forecasted
  • Severity (mild, moderate, severe, very severe)
Drugs profiled
  • Advair
  • Arcapta
  • Breo
  • Daliresp
  • Seebri
  • Spiriva
  • Symbicort
  • Tudorza
  • Ultibro
  • Anoro
  • LAS40464
  • PT003
  • olodaterol/tiotropium
  • umeclidinium
  • vilanterol


Key Findings

Long-acting beta 2 agonists/long-acting anticholinergic (LABA/LAMA) combination inhalers are highly anticipated and will see high uptake, particularly among the severe and very severe populations. Once-daily LABA/LAMAs will address the needs of patients for simplified dosing regimens and will achieve greater uptake than twice-daily inhalers. Overall, this drug class will become a leading class of therapy for the management of COPD. With this class expected to see high commercial success in the already established COPD market, it is clear that the market continues to hold attractive opportunities for developers which carefully consider the needs of the patient population.

> Download your free sample > Contact us to find out more

Datamonitor Healthcare is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726